Literature DB >> 10639380

In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B.

C B Moore1, C M Walls, D W Denning.   

Abstract

The in vitro activity of BMS-207147 against 80 clinical isolates of Aspergillus was compared with that of itraconazole and amphotericin B, using a validated microtiter method. Geometric mean MICs (in microg/ml) were as follows: 1.71 for BMS-207147, 0.67 for itraconazole, and 0.63 for amphotericin B. The range of concentrations of each drug was 0.125 to >16 microg/ml. Aspergillus fumigatus was significantly more susceptible to BMS-207147 (P < 0. 05) than A. terreus and A. flavus. No BMS-207147-resistant A. fumigatus isolates were identified, though eight itraconazole-resistant (MIC, >8 microg/ml) isolates were. BMS-207147 is active against Aspergillus spp. at slightly high concentrations compared with itraconazole and amphotericin B.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10639380      PMCID： PMC89701          DOI： 10.1128/AAC.44.2.441-443.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B.

Authors:  K L Oakley; C B Moore; D W Denning
Journal:  J Antimicrob Chemother       Date:  1998-07       Impact factor: 5.790

2.  Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection.

Authors:  E M Johnson; K L Oakley; S A Radford; C B Moore; P Warn; D W Warnock; D W Denning
Journal:  J Antimicrob Chemother       Date:  2000-01       Impact factor: 5.790

3.  In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp.

Authors:  K L Oakley; C B Moore; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus.

Authors:  K L Oakley; G Morrissey; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

5.  Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis.

Authors:  K Hata; J Kimura; H Miki; T Toyosawa; M Moriyama; K Katsu
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

6.  In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum.

Authors:  K Hata; J Kimura; H Miki; T Toyosawa; T Nakamura; K Katsu
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

7.  Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection.

Authors:  D W Denning; S A Radford; K L Oakley; L Hall; E M Johnson; D W Warnock
Journal:  J Antimicrob Chemother       Date:  1997-09       Impact factor: 5.790

8.  Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma.

Authors:  J Berenguer; N M Ali; M C Allende; J Lee; K Garrett; S Battaglia; S C Piscitelli; M G Rinaldi; P A Pizzo; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

9.  In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole.

Authors:  M A Pfaller; S A Messer; R J Hollis; R N Jones; G V Doern; M E Brandt; R A Hajjeh
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

10.  Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome.

Authors:  V A Morrison; R J Haake; D J Weisdorf
Journal:  Am J Med       Date:  1994-06       Impact factor: 4.965
View more
  11 in total

Review 1.  Pharmacokinetics of antifungal agents in children.

Authors:  Kevin Watt; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Early Hum Dev       Date:  2011-02-01       Impact factor: 2.079

2.  In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Emilia Mellado; Guillermo Garcia-Effron; Araceli Monzon; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

3.  Identification of Aspergillus fumigatus and related species by nested PCR targeting ribosomal DNA internal transcribed spacer regions.

Authors:  J Zhao; F Kong; R Li; X Wang; Z Wan; D Wang
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

Review 4.  Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole.

Authors:  Kevin Watt; Paolo Manzoni; Michael Cohen-Wolkowiez; Stefano Rizzollo; Elena Boano; Evelyne Jacqz-Aigrain; Daniel K Benjamin
Journal:  Curr Drug Metab       Date:  2013-02       Impact factor: 3.731

5.  In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Emilia Mellado; Guillermo Garcia-Effron; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 6.  Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.

Authors:  Helen W Boucher; Andreas H Groll; Christine C Chiou; Thomas J Walsh
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Proteomic and transcriptomic analysis of Aspergillus fumigatus on exposure to amphotericin B.

Authors:  Poonam Gautam; Jata Shankar; Taruna Madan; Ravi Sirdeshmukh; Curam Sreenivasacharlu Sundaram; Wasudev Namdeo Gade; Seemi Farhat Basir; Puranam Usha Sarma
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

Review 8.  Treatment and prophylaxis of invasive candidiasis.

Authors:  Nidhi Tripathi; Kevin Watt; Daniel K Benjamin
Journal:  Semin Perinatol       Date:  2012-12       Impact factor: 3.300

9.  Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Caron A Lyman; Andreas H Groll; Diana Mickiene; Joanne Peter; John Bacher; Kristin Roussillon; Melissa Hemmings; Derrek Armstrong; Nilo A Avila; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

10.  Small Intestinal Infections.

Authors:  Saurabh Mehandru; Edmund J. Bini
Journal:  Curr Treat Options Gastroenterol       Date:  2001-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.